无产前保健孕妇的床旁HIV病毒载量检测:成本效果分析
本研究构建决策分析模型,比较床旁HIV RNA病毒载量检测指导分娩与全部常规剖宫产在1275例无产前保健、足月分娩的HIV阳性孕妇中的成本与结局。结果发现病毒载量检测组新生儿HIV感染更多,成本增加3,883,371美元,质量调整生命年减少63,仅在特定阈值下才具成本效果。
要点
- 在无产前保健的HIV阳性孕妇中,床旁病毒载量检测指导分娩较全部常规剖宫产新生儿HIV感染更多。
- 病毒载量检测策略成本增加3,883,371美元,质量调整生命年减少63。
- 仅在垂直传播率低于0.68%或常规剖宫产OR高于0.885时,病毒载量检测才具成本效果。
核心结论
- 对于无产前保健的HIV感染孕妇,床旁病毒载量检测指导分娩方式较全部常规剖宫产成本增加且效果降低,即使纳入剖宫产下游并发症后亦然。
研究设计与样本
- 使用TreeAge软件构建决策分析模型,比较HIV RNA病毒载量检测与全部常规剖宫产,理论队列为1275例无产前保健、足月分娩的HIV阳性孕妇,该人数为美国每年估计的无产前保健HIV阳性孕妇数。
- 模型纳入第二次妊娠和分娩以评估剖宫产的下游影响,主要结局为母婴传播、分娩方式、剖宫产相关并发症、成本和质量调整生命年,模型输入来自文献并在敏感性分析中变化,成本效果阈值为100,000美元/质量调整生命年。
- 床旁检测的平均每次成本为15.22美元。
主要发现
- 病毒载量检测组较全部常规剖宫产组新生儿HIV感染更多,因该策略中更频繁的阴道分娩导致病毒暴露。
- 未观察到孕产妇死亡,剖宫产相关并发症无差异。
- 病毒载量检测组较全部常规剖宫产组成本增加3,883,371美元,质量调整生命年减少63。
- 在100,000美元/质量调整生命年阈值下,仅当高病毒载量孕妇的垂直传播率低于0.68%(基线16.8%)且全部常规剖宫产相较阴道分娩的垂直传播比值比高于0.885(基线0.3)时,病毒载量检测才具成本效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Routine cesarean delivery has been shown to decrease mother-to-child-transmission of HIV in women with high viral load greater than 1000 copies/mL; however, women presenting late in pregnancy may not have viral load results before delivery. OBJECTIVE: Our study investigated the costs and outcomes of using a point-of-care HIV RNA viral load test to guide delivery compared with routine cesarean delivery for all in the setting of unknown viral load. STUDY DESIGN: A decision-analytic model was constructed using TreeAge software to compare HIV RNA viral load testing vs routine cesarean delivery for all in a theoretical cohort of 1275 HIV-positive women without prenatal care who presented at term for delivery, the estimated population of HIV-positive women without prenatal care in the United States annually. TreeAge Pro software is used to build decision trees modeling clinical problems and perform cost-effectiveness, sensitivity, and simulation analysis to identify the optimal outcome. The average cost per test was $15.22. To examine the downstream impact of a cesarean delivery and because most childbearing women in the United States will deliver 2 children, we incorporated a second pregnancy and delivery in the model. Primary outcomes were mother-to-child transmission, delivery mode, cesarean delivery-related complications, cost, and quality-adjusted life years. Model inputs were derived from the literature and varied in sensitivity analyses. The cost-effectiveness threshold was $100,000/quality-adjusted life year. RESULTS: Measuring viral load resulted in more HIV-infected neonates than routine cesarean delivery for all due to viral exposure during more frequent vaginal births in this strategy. There were no observed maternal deaths or differences in cesarean delivery-related complications. Quantifying viral load increased cost by $3,883,371 and decreased quality-adjusted life years by 63 compared with routine cesarean delivery for all. With the threshold set at $100,000/quality-adjusted life year, the viral load test is cost-effective only when the vertical transmission rate in women with high viral load was below 0.68% (baseline: 16.8%) and when the odds ratio of vertical transmission with routine cesarean delivery for all compared with vaginal delivery was above 0.885 (baseline: 0.3). CONCLUSIONS: For HIV-infected pregnant women without prenatal care, quantifying viral load to guide mode of delivery using a point-of-care test resulted in increased costs and decreased effectiveness when compared with routine cesarean delivery for all, even after including downstream complications of cesarean delivery.
引用
- Avram CM, Greiner KS, Tilden E, et al. Point-of-care HIV viral load in pregnant women without prenatal care: a cost-effectiveness analysis. Am J Obstet Gynecol. 2019. PMID: 31229430. doi:10.1016/j.ajog.2019.06.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。